• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Phase II/III studies show high efficacy and safety of fexinidazole, the first oral treatment for sleeping sickness

Results open possibility of paradigm shift in treatment of deadly disease

Home > Press releases

Phase II/III studies show high efficacy and safety of fexinidazole, the first oral treatment for sleeping sickness

Results open possibility of paradigm shift in treatment of deadly disease

Healthworkers from mobile screening teams look through microscopes to check blood samples for sleeping sickness
Geneva, Switzerland — 4 Nov 2017
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • English
    • English
    • Español
    • Français
    • Português

The first all-oral treatment for Trypanosoma brucei gambiense human African trypanosomiasis (g-HAT) has been proven to be effective and safe, according to the results of clinical trials led by the Drugs for Neglected Diseases initiative (DNDi) and its partners, published today in The Lancet.

Transmitted by the bite of an infected tsetse fly, HAT (or sleeping sickness) is usually fatal without treatment. g-HAT accounts for 98% of recorded sleeping sickness cases.

Between 2012 and 2016, an open-label randomized pivotal Phase II/III clinical trial compared the efficacy and safety of the new treatment, fexinidazole, with today’s first-line treatment, nifurtimox-eflornithine combination therapy (NECT), in meningo-encephalitic (stage-2) g-HAT patients. 394 patients were recruited across 10 sites in the Democratic Republic of Congo (DRC) and Central African Republic. Treatment success rates of 91.2% were measured for fexinidazole, with 97.6% for NECT, 18 months after the end of treatment. The results show that fexinidazole is effective within a predetermined acceptability margin, set following a survey with practitioners, based on the significant advantages of having a first-line treatment that is oral. There were no major differences in safety.

“NECT is extremely effective in treating patients for sleeping sickness and has played a central role in reducing the global burden of this deadly disease to under 2,500 cases a year today. But it involves multiple injections and requires substantial hospital infrastructure which limit access to patients living in remote areas, and poses a heavy burden on the health system,” said Dr Victor Kandé, Neglected Tropical Diseases Expert Advisor, Ministry of Health of the DRC, principal investigator of the trial and lead author of the Lancet article. “An oral treatment would make a real difference as it would remove many barriers to treatment, not least the need for qualified medical and nursing staff to administer parenteral treatment.”

Until NECT was introduced by DNDi and partners, g-HAT was often treated with an arsenic derivative that killed 1 in 20 patients. NECT has replaced this treatment for g-HAT, but patients still need a lumbar puncture to determine which stage of the disease they have. Fexinidazole is effective for both stages of the disease, so will remove this need.

Two additional studies confirmed the efficacy of fexinidazole in haemo-lymphatic (stage-1) and early-stage-2 g-HAT patients (98.7%), and in children (97.6%), 12 months after the end of treatment. 230 adults were recruited as a part of the safety and efficacy trial in stage-1 and early-stage-2 patients, and 125 children for the paediatric trial. Overall, these additional studies did not reveal any new safety signals regarding the use of fexinidazole.

“Having an oral drug like fexinidazole as a future first-line treatment, with NECT as a second line, opens the way for a paradigm shift in how national programmes and the World Health Organization (WHO) can tackle the disease, as well as facilitating the integration of disease management in the health system,” said Dr Nathalie Strub-Wourgaft, DNDi Medical Director. “In due course, treatment could be administered at the primary healthcare level, removing the need for hospitalization, and potentially, for the first time, patients could even take their entire treatment at home.”

These results enable Sanofi, DNDi’s industrial partner on fexinidazole, to proceed with steps towards regulatory approval through the European Medicines Agency (EMA) Article 58 procedure (which allows the EMA to give opinions, in co-operation with WHO, for the evaluation of certain medicinal products for human use that are intended exclusively for markets outside of the European Union), with a view to ensuring patient access to fexinidazole in HAT-endemic countries.

“The history of sleeping sickness shows that the disease is prone to resurging when it seems under control,” said Dr Gautam Biswas, Director ad interim, WHO Department of Control of Neglected Tropical Diseases. “Fexinidazole could make an important contribution towards sustaining the elimination of sleeping sickness.”

The DRC national control programme (the Programme national de lutte contre la trypanosomiase humaine africaine, or PNLTHA) played a key role in the implementation of the studies.

“The development of fexinidazole over the past decade bears witness to the value of the alternative non-profit R&D model, and in the DNDi approach of forging strong partnerships involving WHO, disease-endemic country Ministries of Health and national control programmes, and the pharmaceutical industry,” said Dr Bernard Pécoul, DNDi Executive Director. “This accomplishment is far from DNDi’s alone, but is one shared with all our partners and donors.”

Media contacts

  • James Arkinstall, DNDi (Europe) +41 79392 9823
  • Ilan Moss, DNDi (US) +1 646 266 5216

 

NOTES

About sleeping sickness

Sleeping sickness (also known as human African trypanosomiasis or HAT) is caused by two subspecies of parasite, both transmitted by the tsetse fly. Trypanosoma brucei gambiense, which causes g-HAT, accounts for 98% of reported sleeping sickness cases, and is endemic in 24 countries of West and Central Africa. The majority of HAT patients are reported in the Democratic Republic of Congo, where 84% of cases are reported, followed by the Central African Republic, Guinea and Chad.

About NECT

Until recently, the best available treatment for sleeping sickness, eflornithine monotherapy, involved 56 intravenous infusions and14 days in hospital, and was so complex to distribute and use in resource-poor settings that clinicians often resorted to using melarsoprol, a highly toxic, arsenic-based drug that killed 5% of those treated with it. Clinical trials developed by Epicentre, Médecins Sans Frontières/Doctors without Borders (MSF) and DNDi confirmed the non-inferiority of NECT, a simpler and shorter regimen presenting considerable benefits for patients compared to eflornithine. NECT is today used to treat 100% of reported stage-2 g-HAT cases.

About fexinidazole

In the 1970s, Hoechst (now part of Sanofi) had initiated but did not pursue pre-clinical development of fexinidazole. In 2005, the compound was identified by DNDi as having activity against the sleeping sickness parasite. Pre-clinical studies began in 2007. In 2009, DNDi and Sanofi concluded a collaboration agreement for the development, manufacturing, and distribution of fexinidazole, with DNDi responsible for pre-clinical, clinical, and pharmaceutical development, and Sanofi responsible for industrial development, registration, production and distribution of the drug. Phase I studies began in 2010, and the Phase II/III pivotal clinical study in 2012.

DNDi’s fexinidazole programme is supported by grants from the Bill & Melinda Gates Foundation, the UK Department for International Development, the Dutch Ministry of Foreign Affairs, the German Federal Ministry of Education and Research, the German Development Agency, the French Development Agency, the French Ministry for Europe and Foreign Affairs, the Norwegian Agency for Development Cooperation, the Spanish Agency for International Development Cooperation, the Republic and Canton of Geneva, International Solidarity Service, Switzerland, the Swiss Agency for Development and Cooperation, Médecins Sans Frontières/Doctors without Borders, and other private foundations and individuals.

About DNDi

A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected diseases, in particular human African trypanosomiasis, leishmaniasis, Chagas disease, filarial infections, mycetoma, paediatric HIV, and hepatitis C. NECT is one of the seven treatments delivered by DNDi since its inception in 2003. Fexinidazole is DNDi’s first new chemical entity to successfully complete Phase II/III trials.

www.dndi.org

Photo credit: Neil Brandvold-DNDi

Policy advocacy Partnership Sleeping sickness

Read, watch, share

Loading...
Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

Lab activities
News
20 Feb 2023

First in-person Dengue Alliance meeting brings together experts from dengue-endemic countries to develop treatments for a growing viral threat

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo